news
Over £100mn in fines for pharma firms hiking prices of crucial thyroid drug
The Competition and Markets Authority fines Advanz and two others for hiking prices of liothyronine tablets by 1,110 percent in eight years.
List view / Grid view
UK National Health Service (NHS)
news
British pharma’s 2021 Code of Practice now in force
The ABPI’s 2021 pharmaceutical industry Code of Practice aims to increase transparency, encourage collaboration and improve patient care.
article
New regulatory guidance could lead to UK biosimilar boom
New guidance on the licensing of biosimilar products that reduces unnecessary clinical trials is expected to put the UK ahead of Europe and facilitate a boom in these essential life-saving medicines, creating greater patient access and saving the National Health Service (NHS) hundreds of millions of pounds. It could also…
article
Ten recommendations to foster the UK’s medicinal cannabis market
In this article, EPR summarises the list of 10 recommendations for the UK Government, published by experts in the medicinal cannabis industry, to ensure the UK capitalises on the opportunities afforded by the market.
article
Building the UK’s domestic pharma manufacturing capability
In this article, Rich Quelch, Global head of marketing at Origin, discusses how the UK’s pharmaceutical supply chain could be adapted to increase its resilience to future disruptions and the challenges in doing so.
news
NICE recommends ravulizumab for treatment of a rare blood disorder
On the NICE’s recommendation, ravulizumab will be made available to hundreds of patients with paroxysmal nocturnal haemoglobinuria on the UK’s NHS.
article
Introducing NICE’s new board members
European Pharmaceutical Review explores who will be joining the National Institute of Health and Care Excellence (NICE)’s board as a new non-executive director on 1 April 2021.
news
NICE recommends new triple therapy treatment for multiple myeloma
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately 2,000 NHS patients as a second line treatment for multiple myeloma.
news
NICE recommends treatment for non-squamous, non-small cell lung cancer
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
news
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
article
Cannabinoid series: medicinal cannabis and Brexit
Sarah Ellson from Fieldfisher spoke with European Pharmaceutical Review to discuss the position of medicinal cannabis in the UK and the impacts of Brexit.
news
First person receives Pfizer and BioNTech COVID-19 vaccine in UK
A 90-year old woman is the first person to receive BNT162b2, the Pfizer and BioNTech COVID-19 vaccine, outside of clinical trials.
article
What the world can learn from the UK’s pharmaceutical industry
Through the recent coronavirus crisis, the UK’s pharmaceutical sector has performed strongly and delivered innovation at a time when it was most needed. In this article, Dr Cheryl Teoh discusses how the industry has been set up for success.
news
NICE to simplify how medicines are selected for evaluation
NICE has launched a public consultation for suggestions on updating how it selects the topics to develop guidance on, to improve medicine evaluations.
news
UK leads Europe in Phase I and Phase II trials, ABPI findings show
The ABPI has found that the UK is leading the rest of Europe in early-stage clinical trials and makes suggestions on how the country can maintain this position.